Integra LifeSciences (IART)

The business is organised around two main areas: Codman Specialty Surgical and Tissue Technologies. Codman Specialty Surgical includes instruments, devices, and related technologies used in neurosurgical and other specialty surgical procedures. This segment is a major contributor to company revenue and reflects Integra’s long-standing position in areas such as cranial access, cerebrospinal fluid management, and surgical instrumentation.

Tissue Technologies focuses on products that support wound reconstruction, soft tissue repair, and regenerative therapy. Integra is widely associated with the use of biologic and collagen-based materials designed to help clinicians manage complex wounds and surgical reconstruction cases. The company’s products are used across acute care settings, outpatient facilities, and specialist practices.

Integra sells its products in the United States and international markets including Europe and Asia Pacific, although domestic sales represent its largest source of revenue. Its customers operate in highly regulated healthcare systems, which means product quality, clinical evidence, regulatory approvals, and surgeon adoption are important drivers of performance.

For investors, Integra LifeSciences represents exposure to specialised medical devices and regenerative medicine rather than broad consumer healthcare. Its prospects are linked to procedure volumes, hospital spending, innovation in surgical care, portfolio execution, and competition from other medical technology companies.